What's Happening With Novo Nordisk Stock Today?

Benzinga03-27 01:47

Hims & Hers said it is now making a wide range of Novo Nordisk's GLP‑1 drugs available to eligible customers, including the Wegovy pill, currently the only FDA‑approved oral GLP‑1 treatment for weight...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622569898?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/26/Novo-Nordisk-Logo-Displayed-On-Smartphon.jpeg?optimize=medium&dpr=2&auto=webp&width=260","is_english":true,"pubTime":"2026-03-27 01:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622569898","market":"hk","top_or_hot":-1,"title":"What's Happening With Novo Nordisk Stock Today?","media":"Benzinga","content":"<div>\n<p>Hims & Hers said it is now making a wide range of Novo Nordisk's GLP‑1 drugs available to eligible customers, including the Wegovy pill, currently the only FDA‑approved oral GLP‑1 treatment for weight...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/03/51490943/whats-happening-with-novo-nordisk-stock-today\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's Happening With Novo Nordisk Stock Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's Happening With Novo Nordisk Stock Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-27 01:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/26/03/51490943/whats-happening-with-novo-nordisk-stock-today><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hims & Hers said it is now making a wide range of Novo Nordisk's GLP‑1 drugs available to eligible customers, including the Wegovy pill, currently the only FDA‑approved oral GLP‑1 treatment for weight...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/03/51490943/whats-happening-with-novo-nordisk-stock-today\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ1G4Q59.USD","symbol_name":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51490943/whats-happening-with-novo-nordisk-stock-today","article_id":"2622569898","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/26/Novo-Nordisk-Logo-Displayed-On-Smartphon.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51490943/whats-happening-with-novo-nordisk-stock-today","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622569898","pubTimestamp":1774547220,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Novo Nordisk A/S (NYSE:NVO) shares are moving higher on Thursday. Hims & Hers Health Inc (NYSE:HIMS) announced it will begin offering several of the Novo's FDA‑approved GLP‑1 medications, including the newly launched Wegovy pill.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4588":"碎股","BK4007":"制药","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","NVO":"诺和诺德","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","NVOH":"Novo Nordisk A/S B Shares ADRhedged","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","NVOX":"2倍做多NVO ETF-Defiance"},"translate_title":"诺和诺德股票今天发生了什么？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVOX":0.6,"NVO":1.98,"NVOH":0.6},"content_text":"Hims & Hers said it is now making a wide range of Novo Nordisk's GLP‑1 drugs available to eligible customers, including the Wegovy pill, currently the only FDA‑approved oral GLP‑1 treatment for weight loss.\nEligible users can now be prescribed Novo Nordisk treatments that have been shown to help patients lose up to 20% of their body weight, depending on an independent provider's clinical assessment. Available options include Wegovy injections in multiple strengths — 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg — as well as oral doses of 1.5 mg, 4 mg, 9 mg and 25 mg. A 7.2 mg injectable dose is expected to be added soon. Pricing starts at $149 per month.\nOzempic injection pens, which are approved for Type 2 diabetes, will also be offered to eligible patients based on clinical judgment, though the drug is not approved for weight loss.\nHims & Hers CEO Andrew Dudum said the move represents \"an important next step toward building a better model of healthcare that works for everyday people,\" adding that collaboration between healthcare innovators helps ensure access keeps pace with medical advances.\nNovo Nordisk is trading 2.5% below its 20-day SMA and 23.7% below its 100-day SMA, keeping the intermediate trend pointed down even as the stock tries to stabilize. Shares are down 48.54% over the past 12 months and are positioned much closer to their 52-week low than their high.\nRSI is at 30.46, which is neutral but sitting right on the doorstep of oversold conditions after the RSI dipped below 30 on 2026-02-23. Meanwhile, MACD is at -2.4892 versus a signal line of -2.8457, a bullish configuration that suggests downside momentum is easing even though the trend is still damaged.\nRSI in the 30-50 range with bullish MACD indicates momentum leaning bullish.\nAnalyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $97.75. Recent analyst moves include:\nBenzinga Edge Rankings: The Benzinga Edge scorecard for Novo-Nordisk highlights its strengths and weaknesses compared to the broader market.\nThe Verdict: Novo-Nordisk’s Benzinga Edge signal reveals a fundamentals-strong but price-weak setup, with elite Growth and Quality scores contrasted by very bearish Momentum. For longer-term investors, that often frames the stock as a \"watch for trend reversal\" candidate — especially if it can hold $36.00 support and start reclaiming key moving averages.\nNVO Price Action: Novo Nordisk shares were up 1.24% at $36.78 at the time of publication on Thursday. The stock is trading near its 52-week low of $35.85, according to Benzinga Pro.\nImage: Piotr Swat/Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622569898","isCrawlerRequest":true}